Eularis

Eularis News Room Archive and Profile

Eularis is the leading provider of next-generation advanced AI analytics to the Pharmaceutical market. The Artificial Intelligence powering Eularis analytics enables marketing, analytics and sales executives to achieve faster profitable growth.

Since 2003 the company has developed significant experience in the global Pharmaceutical market through client engagements with Boehringer Ingelheim, Merck, Pfizer, Roche, Shire, and many others.

Engage with Eularis

Learn more online at: http://www.Eularis.com/

Follow:  Twitter  |  Facebook

RSS News Feed for Eularis

Press Releases from Eularis :

Pharma companies gain competitive advantage from 1 day Masterclass on Artificial Intelligence in Pharma sales and marketing

EULARIS

NEW YORK, N.Y., Aug. 2, 2016 (SEND2PRESS NEWSWIRE) — Eularis announces the release of their one-day Masterclass “Using Artificial Intelligence to Transform Sales and Revenue: What Pharma Need to Know.” Many Pharma sales and marketing teams do not understand the relevance, nor the critical importance, of AI to achieve stronger results in their roles, and believe it is not relevant to them or their job. This is an incorrect assumption.

E-VAI – the Artificial Intelligence Platform from Eularis Changes the Rules of the Marketing in Pharma

Eularis

NEW YORK, N.Y. and Tokyo, Sept. 15, 2015 (SEND2PRESS NEWSWIRE) — Eularis announces today the release of E-VAI, the latest development in sophisticated artificial intelligence technology delivering next generation analytics and decision making to Pharma marketers globally. E-VAI changes the game for marketers struggling to understand and get value from their marketing.

Eularis Updates Reports That Help Pharmaceutical Companies Do More for Real Growth Than Simply Downsizing

Eularis

LONDON, U.K. (SEND2PRESS NEWSWIRE) — The pharmaceutical industry is facing unprecedented challenges on many fronts – a slew of patient expiries, a lack of blockbusters in the pipeline to replace the patent expiries, decreasing growth in many major markets, generic competition, constantly changing regulatory and competitive environment rendering old tools for analysis obsolete, increased pressure on CEOs to deliver shareholder growth resulting in budget cuts, downsizing, and less than optimal results.

Pharmaceutical eMarketing using Social Media: How to Use It Effectively, Meet the Challenges (Regulatory and Others) and Measure Results in Dollar Terms

Eularis

NEW YORK, N.Y. and LONDON, U.K. (SEND2PRESS NEWSWIRE) — Eularis is announcing the release of its report ‘How To Harness The Power Of Social Media In Pharmaceutical eMarketing.’ This report puts to rest the issues around ‘can’t,’ and shows Pharmaceutical marketers how they can utilize social media networks effectively to meet their marketing objectives.

Eularis Releases Comprehensive Report on Effective and Measurable Pharmaceutical eMarketing using Social Media

Eularis

NEW YORK, N.Y., and LONDON, U.K., May 18 (SEND2PRESS NEWSWIRE) — Eularis is announcing the release of an update to its report ‘Pharmaceutical eMarketing: Building Brands, Relationships & Business Through Web 2.0 and Beyond.’ The comprehensive report has been created to demystify the world of eMarketing and Social Media to provide Pharmaceutical marketers with a competitive edge and the latest information on how to use these emerging tools.

MEDIA ALERT – Eularis to Hold Pharmaceutical Marketing ROI MasterClass in London

Eularis

LONDON, U.K., May 18 (SEND2PRESS NEWSWIRE) — Dr. Andree Bates, President of the Pharmaceutical analytics company Eularis, will be delivering a MasterClass on how to tell if you are making the wrong marketing decision. The Pharmaceutical Industry is under significant pressure to consider its costs very carefully. Since marketing budgets often represent a major portion of a company’s cost base, they can easily become the target of budget cuts. The pressure to measure marketing return and effectiveness has never been stronger.

Eularis Analyzes Pre-Launch Brand Planning with New Pharmaceutical Industry Report

Eularis

NEW YORK, LONDON, TOKYO, Nov. 17 (SEND2PRESS NEWSWIRE) — In today’s environment, Pharmaceutical companies find themselves in a bind. Drug launches used to be able to achieve high sales and profits – until recently. Every Pharma company today is hoping to achieve their own immediate winners, the drugs that are successful right from the start and provide years of business-sustaining profit. However, recent studies have shown that seven out of ten drugs launched in the last five years have failed to repay their R&D investment.

Eularis Releases First-Ever Study on ROI of Pre-Launch Named Patient Programmes

Eularis

NEW YORK, N.Y. and LONDON, U.K., Sept. 16 (SEND2PRESS NEWSWIRE) — Eularis today announced the release of a first-ever study on the ROI of named patient programmes (NPP), also known as compassionate use programs. The paper, ‘Implementing a pre-launch named patient programme – evidence of increased market share,’ provides pharmaceutical companies with insight and mathematical justification into the cash market share and revenue impact of pre-launch NPPs on brands, while outlining the benefits and challenges that they create.

Eularis Analyzes Most Effective Generics Defense Strategies with New Pharmaceutical Industry Report

Eularis

NEW YORK, N.Y. and TOKYO, JAPAN, July 13 (SEND2PRESS NEWSWIRE) — Branded Pharmaceutical companies are painfully aware of the astronomical growth of Generics competition. By the end of this year, Branded drug patents accounting for sales of more than $80 Billion will expire, resulting in major losses in company profits. In the United States, the Generics Industry claims more than 50 percent of all prescriptions filled. Even in Japan, where Generics penetration is notoriously low, changes are afoot.

New Report Examines Pharmaceutical Sales Force Effectiveness

Eularis

LONDON UK, and TOKYO Japan, July 7 (SEND2PRESS NEWSWIRE) — With the ever-increasing pressure to ensure maximum return on investment, sales force effectiveness is becoming a high priority in the global pharmaceutical industry. Reports have shown that while sales forces represent the largest spend in pharma sales and marketing, return on this investment has declined sharply in recent years.

Eularis Releases Update of Its Comprehensive Report on Maximizing the Bottom Line in Pharmaceutical Marketing

Eularis

LONDON, UK and TOKYO Japan, June 30 (SEND2PRESS NEWSWIRE) — Eularis is announcing the release of an update to its report, Ensuring Profitable Return-on-Investment (ROI) in Pharmaceutical Marketing: Using Analytics and Metrics to Improve the Bottom Line. Originally offered in February 2007, the comprehensive report has been revised to provide pharmaceutical marketers with a competitive edge and the latest research information.

Eularis to Address Marketing Return at Japanese Pharmaceutical Marketing Excellence Conference

Eularis

TOKYO and LONDON, U.K., May 12 (SEND2PRESS NEWSWIRE) — Dr. Andree Bates, president of the New York and London-based pharmaceutical analytics company Eularis, will be delivering a presentation on how to tell if you are making the wrong marketing decision. The Pharmaceutical Marketing Excellence conference takes place in Tokyo, Japan.

Eularis to Address Making the Right Research Decision for ROI

Eularis

NEW YORK, N.Y. and LONDON, U.K., April 21 (SEND2PRESS NEWSWIRE) — Dr. Andree Bates, president of the pharmaceutical analytics company Eularis, will be delivering a presentation on Making the Right Research Decision for ROI – The Link Between Research and Decisions on Bottom Line Return, at 3rd Annual Pharmaceutical Market Research Summit.

Eularis Exposes Hidden Barriers to Patient Adherence with New Pharmaceutical Industry Report

Eularis

NEW YORK, N.Y. and LONDON, U.K., March 12 (SEND2PRESS NEWSWIRE) — Costing the global pharmaceutical industry an estimated $30 billion per year and causing an estimated 125,000 deaths per year in the United States, patient non-adherence is a looming issue in the healthcare industry. Eularis has responded to this problem with a new report, available today, titled, ‘Ensuring Profitable Patient Adherence Programs.’

MEDIA ALERT: Eularis to Address Marketing Return at Measuring Marketing ROI in Pharma Conference in London

Eularis

NEW YORK, N.Y. and LONDON, U.K., March 10 (SEND2PRESS NEWSWIRE) — Dr. Andree Bates, president of the pharmaceutical analytics company Eularis, will be delivering a presentation on meeting the challenges of measuring ROI within the changing dynamics of the pharma industry.

New Report Examines Pharmaceutical Sales Force Effectiveness

Eularis

LONDON, U.K. and NEW YORK, N.Y. – Nov. 20 (SEND2PRESS NEWSWIRE) — With the ever-increasing pressure to ensure maximum return on investment, sales force effectiveness is becoming a high priority in the global pharmaceutical industry. Reports have shown that while sales forces represent the largest spend in pharma sales and marketing, return on this investment has declined sharply in recent years.

MEDIA ALERT: Eularis to Address Marketing Return at Pharmaceutical Marketing Society Half-day Conference: ROI or RIP?

Good Gets Better Publishing

NEW YORK, N.Y. and LONDON, U.K. – Nov. 20 (SEND2PRESS NEWSWIRE) — Dr. Andree Bates, president of the pharmaceutical analytics company Eularis, will be delivering a presentation on marketing return at the Pharmaceutical Marketing Society Half-day Conference: ROI or RIP. At 2:30 p.m. on Monday 26 November 2007, Dr. Bates will deliver a presentation titled, ‘What Can Be Measured?’

Eularis Releases Update of Its Comprehensive Report on Maximizing the Bottom Line in Pharmaceutical Marketing


NEW YORK, N.Y. and LONDON, U.K. – Oct. 30 (SEND2PRESS NEWSWIRE) — Eularis is announcing the release of an update to its report, ‘Ensuring Profitable Return-on-Investment (ROI) in Pharmaceutical Marketing: Using Analytics and Metrics to Improve the Bottom Line.’ Originally offered in February 2007, the comprehensive report has been revised to provide pharmaceutical marketers with a competitive edge and the latest research information.

Eularis Announces New Corporate Name and Expanded Product Offerings


NEW YORK, N.Y. and LONDON, U.K. – Sept. 24 (SEND2PRESS NEWSWIRE) — Campbell Belman, an established pharmaceutical analytics company, today introduces its new name: Eularis. This announcement reflects the significant growth the Company has achieved across its full range of pharmaceutical analytics products, which have helped tailor the advertising and marketing programs of its global top-tier clients.